Truven Extends Free Access to Five Micromedex Mobile Apps For Apple

View Comments
Truven Health

ANN ARBOR (WWJ) – Truven Health Analytics announced the release of the latest version of its Micromedex Apple iPhone apps, giving current customers outside the United States and Canada on-the-go access to evidence-based clinical content for free.

The applications released to customers on Apple iTunes this month include:
• Micromedex Drug Information
• Micromedex Drug Interactions
• Micromedex IV Compatibility
• Micromedex Pediatrics Essentials
• Micromedex NeoFax Essentials

Micromedex Drug Information is currently one of the most popular medical apps in Apple’s App Store, totalling over 1.5 million downloads since its original release. The app delivers actionable recommendations to take users beyond the drug package insert to find off-label indications, dosing recommendations, therapeutic class, administration, monitoring, toxicology, clinical teaching, and more, giving customers access to the highest quality evidence available. With this release, the Drug Information app is now available outside the U.S. and Canada to current Micromedex subscribers at no charge. The app remains available for free to all users in the U.S. and Canada.

With Micromedex Drug Interactions, customers can check up to 50 patient medications simultaneously for potentially harmful interactions. Severity ratings are assigned to each interaction, ranging from contraindicated to minor. Additionally, users can see why the drugs in question interact, how the results of those interactions will present in the patient, and recommendations for monitoring patient outcomes. This app is now available to Micromedex customers globally at no charge.

Users of the Micromedex IV Compatibility app can rely on the ultimate authority on IV compatibility information — Trissel’s 2 Clinical Pharmaceutics Database — to enhance patient safety when administering IV medications. This app provides access to drug-solution and drug-drug compatibility results, including contributing factors such as the physical compatibility, storage, study period, container, and chemical stability. This app is now available to Micromedex customers globally at no charge.

Micromedex Pediatrics Essentials empowers customers with comprehensive, pediatric-specific, evidence-based information required to treat this complex population. This mobile app provides reliable access to the details required to confidently make accurate and informed treatment decisions at the point of care. This app is now available globally at no charge to customers with a Micromedex subscription to Pediatric Drug Information.

Micromedex NeoFax Essentials incorporates evidence-based information beyond the FDA-approved indications. It provides access at the point of care to comprehensive, neonatal-specific, evidence-based information required to treat this complex population. This app is available globally at no charge to customers with a Micromedex subscription to NeoFax.

This release provides Micromedex subscribers outside the U.S. and Canada with free access to five mobile apps currently available in those countries. All were designed to provide health care professionals with the information they need, when and where they need it to make informed treatment decisions with confidence. Micromedex customers worldwide can access these applications for free with the use of an organizational customer password.

“As the use of mobile devices increase in clinical settings it becomes increasingly important for our evidence-based resources to be accessible that way,” said Thomas Hegelund, executive vice president at Truven Health Analytics. “By providing global access to these mobile apps, clinicians have easy mobile access to the trusted content and fast answers they need to make informed clinical decisions.”

For more information and to download each application, go to http://www.micromedex.com/mobile/global.

View Comments
blog comments powered by Disqus
Follow

Get every new post delivered to your Inbox.

Join 2,053 other followers